Transgene Biotek
TRANSGENEBIOTEKLTD NSE
Transgene Biotek
Healthcare ServicesNSE: TRANSGENEBIOTEKLTD BSE: 526139 Healthcare Service Provider
Key Fundamentals
MicrocapHealthcare Service ProviderHealthcare ServicesMarket Cap
₹21.55 Cr
Volatility
Moderate
P/E Ratio
-13.6
EBITDA
₹-0.54 Cr
Return on Equity
-6.74%
Debt to Equity
2.05
Book Value
₹1.11
EPS
₹0
52W High
₹4.5
52W Low
₹1.83
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
4- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
- Company has a low return on equity of -9.77% over last 3 years.
- Company might be capitalizing the interest cost
Growth Rate
Revenue Growth
-79% lower than
3Y
Net Income Growth
136% higher than
3Y
Cash Flow Change
1.2% level than
3Y
ROE
10.13% higher than
3Y
ROCE
-17.5% higher than
3Y
EBITDA Margin (Avg.)
361% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.1 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.08 | 0.08 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 |
| Expenses | 0.22 | 0.17 | 0.16 | 0.32 | 0.46 | 0.13 | 0.17 | 0.62 | 0.18 | 0.13 | 0.1 | 0.33 | 0.12 |
| Operating Profit | -0.12 | -0.12 | -0.11 | -0.27 | -0.41 | -0.07 | -0.09 | -0.54 | -0.13 | -0.08 | -0.05 | -0.28 | -0.06 |
| OPM % | -120% | -240% | -220% | -540% | -820% | -116.67% | -112.5% | -675% | -260% | -160% | -100% | -560% | -100% |
| Other Income | 0.04 | 0.04 | 0.04 | 0.05 | 0.65 | 0.04 | 0.04 | 0.04 | 0 | 0 | 0 | 0.15 | 0 |
| Interest | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.19 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 |
| PBT | -0.13 | -0.13 | -0.12 | -0.27 | 0.2 | -0.07 | -0.09 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 | -0.39 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.13 | -0.13 | -0.12 | -0.27 | 0.2 | -0.07 | -0.09 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 | -0.39 |
| EPS in Rs | -0.02 | -0.02 | -0.02 | -0.04 | 0.03 | -0.01 | -0.01 | -0.09 | -0.06 | -0.05 | -0.05 | -0.06 | -0.05 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.3 | 0.18 | 0.28 | 0.12 | 0.07 | 0 | 0.17 | 0.09 | 0.06 | 0.23 | 0.26 | 0.21 | 0.21 |
| Expenses | 1.9 | 1.32 | 2.84 | 2.22 | 0.75 | 0.87 | 0.7 | 0.55 | 0.68 | 0.83 | 1.38 | 0.75 | 0.68 |
| Operating Profit | -1.6 | -1.14 | -2.56 | -2.1 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.6 | -1.12 | -0.54 | -0.47 |
| OPM % | -533.33% | -633.33% | -914.29% | -1750% | -971.43% | — | -311.76% | -511.11% | -1033.33% | -260.87% | -430.77% | -257.14% | -223.81% |
| Other Income | 0.01 | 0.17 | 0.66 | 7.37 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.18 | 0.78 | 0.15 | 0.15 |
| Interest | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.24 | 1.06 | 1.1 |
| Depreciation | 17.18 | 20.5 | 17.53 | 9.89 | 9.89 | 9.9 | 9.91 | 9.92 | 4.95 | 0.09 | 0.09 | 0.2 | 0.19 |
| PBT | -19.13 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.4 | -6.01 | -0.65 | -0.67 | -1.65 | -1.61 |
| Tax % | 0% | 0% | 0% | 13.98% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -19.14 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.4 | -6.01 | -0.66 | -0.68 | -1.65 | -1.61 |
| EPS in Rs | -2.53 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 | -0.22 | -0.21 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | 116 | 98.67 | -16.9 | -23.34 | -32.13 | -43.1 | -53.53 | -58.39 | -64.4 | -65.06 | -65.74 | -67.39 |
| Borrowings | 14.43 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.01 | 13.11 | 14 | 14.52 | 17.14 |
| Other Liabilities | 138 | 123 | 123 | 124 | 124 | 124 | 123 | 118 | 118 | 118 | 120 | 118 |
| Total Liabilities | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 142 | 142 | 144 | 144 |
| Fixed Assets | 163 | 141 | 61.16 | 50.97 | 41.1 | 31.2 | 21.32 | 11.4 | 6.45 | 6.36 | 7.96 | 9.63 |
| CWIP | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.09 |
| Other Assets | 180 | 172 | 135 | 134 | 134 | 134 | 134 | 134 | 134 | 134 | 134 | 134 |
| Total Assets | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 142 | 142 | 144 | 144 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 3.52 | 6.47 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.1 | 0 | 0 | 1.2 | -0.01 |
| Investing | -4.57 | -6.47 | 0 | 3.05 | 1.74 | 0 | -0.03 | -0.1 | -0.01 | 0 | -1.7 | 0.15 |
| Financing | 1.03 | 0 | 0 | -2.37 | 0 | -0.2 | 0 | 0 | 0 | 0 | 0.78 | -0.36 |
| Net Cash Flow | -0.02 | 0 | 0.02 | 0.05 | 0 | -0.06 | -0.01 | 0 | -0.01 | 0 | 0.28 | -0.22 |
| Free Cash Flow | -1.05 | 0 | 0.02 | 2.74 | -0.01 | 0.14 | -0.02 | 0.1 | 0 | 0 | -0.5 | 0.14 |
| CFO/OP | -220 | -568 | -1 | 30 | 256 | -16 | -2 | -22 | 0 | 0 | -107 | 2 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 19,953 | 3,326 | 13.04 | 30.42 | 52.14 | — | 21.47 | 40.56 | 60.83 | 15.87 | 14.04 | 17.38 |
| Inventory Days | — | — | — | 365 | 365 | 1,460 | 122 | — | 156 | — | — | — |
| Days Payable | — | — | — | 5,019 | 3,528 | 13,870 | 1,460 | — | 1,199 | — | — | — |
| Cash Conversion Cycle | 19,953 | 3,326 | 13.04 | -4,623 | -3,111 | — | -1,317 | 40.56 | -982 | 15.87 | 14.04 | 17.38 |
| Working Capital Days | -8,529 | -16,019 | -14,339 | -39,968 | -62,519 | — | -29,093 | -34,594 | -57,366 | -15,933 | -16,509 | -21,361 |
| ROCE % | -8.83% | -10.86% | -14.69% | -10.97% | -17.91% | -22.11% | -26.56% | -32.31% | -20.01% | -2.07% | -1.75% | -2.36% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Transgene Biotek insights
61 extracted metrics + investor summaries across FY09–FY26.
Documents
2
Compliance-57 (4) : Prior intimation to the beginning of the quarter
13 Apr - Regulation 57 not applicable as no non-convertible securities exist for Q4 FY2026. 13 Apr - Regulation 57 not applicable as no non-convertible securities exist for Q4 FY2026.
3
Compliance-57 (5) : intimation after the end of quarter
13 Apr - Reg. 57(5) not applicable for quarter ended 31 March 2026; no non-convertible securities issued. 13 Apr - Reg. 57(5) not applicable for quarter ended 31 March 2026; no non-convertible securities issued.
4
Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI LODR) Regulations, 2015 For The Quarter Ended On 31St March 2026.
13 Apr - Regulation 32 non-applicability intimated for quarter ended 31 March 2026; no public, rights or preferential issue. 13 Apr - Regulation 32 non-applicability intimated for quarter ended 31 March 2026; no public, rights or preferential issue.
5
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
13 Apr - Transgene Biotek confirms it does not qualify as a Large Corporate under SEBI norms. 13 Apr - Transgene Biotek confirms it does not qualify as a Large Corporate under SEBI norms.
Frequently Asked Questions about Transgene Biotek
What does Transgene Biotek Ltd do?
Incorporated in 1990, Transgene Biotek Ltd
is in the business of Research & Development[1]
Where is Transgene Biotek Ltd (526139) listed?
Transgene Biotek Ltd trades as TRANSGENEBIOTEKLTD on the NSE and under code 526139 on the BSE.
Which sector does Transgene Biotek Ltd belong to?
Transgene Biotek Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the market capitalisation of Transgene Biotek Ltd?
Transgene Biotek Ltd has a market capitalisation of ₹21.55 Cr, which places it in the Small Cap band.
What is the PE ratio of Transgene Biotek Ltd?
Transgene Biotek Ltd trades at a PE ratio of -13.60, on earnings per share of ₹0, against a book value of ₹1.11 per share.
What is the 52-week high and low of Transgene Biotek Ltd?
Over the last 52 weeks Transgene Biotek Ltd has traded between ₹1.83 and ₹4.5.
What is the Return on Equity (ROE) of Transgene Biotek Ltd?
Transgene Biotek Ltd reported a return on equity of -6.74%. Its debt-to-equity ratio is 2.05.
Company Information
Incorporated in 1990, Transgene Biotek Ltd is in the business of Research & Development[1]
Website transgenebiotek.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/526139.md for Transgene Biotek Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.